File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Efficacy of Combination Chemotherapy with Irinotecan (CPT-11) plus Capecitabine in Patients with Metastatic or Advanced Colorectal Carcinoma - a Dual-centre Phase II Study: the MAC-6

TitleEfficacy of Combination Chemotherapy with Irinotecan (CPT-11) plus Capecitabine in Patients with Metastatic or Advanced Colorectal Carcinoma - a Dual-centre Phase II Study: the MAC-6
Authors
KeywordsCapecitabine
CPT-11
irinotecan
metastatic colorectal cancer
Issue Date2008
PublisherWB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/clon
Citation
Clinical Oncology, 2008, v. 20 n. 2, p. 168-175 How to Cite?
AbstractAims: A phase II trial was initiated to evaluate the efficacy and toxicity of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic colorectal cancer. Patients and methods: Patients received a combination of CPT-11 plus capecitabine. CPT-11 was infused intravenously on day 1 every 2 weeks and oral capecitabine was taken twice daily for 5 days every 7 days. Efficacy and toxicities were assessed. Results: Between 2004 and 2005, 43 patients were enrolled. The overall response rate was 51.35%. With a median follow-up of 13 months, the median time to progression was 10 months (95% confidence interval 7.6-12.3 months); the median survival was 15 months (95% confidence interval 13.9-16.9 months). The most common grade 3 haematological and non-haematological toxicities were neutropenia (5.4%), diarrhoea (8.1%) and hand-foot syndrome (2.7%). Conclusions: CPT-11 plus capecitabine with a 14 day cycle showed a comparable response with international phase II data with a 3 weekly regimen and was well tolerated as a first-line palliative chemotherapy in patients with metastatic colorectal cancer. The data should be interpreted with caution due to the limited sample size and should be further confirmed by a phase III randomised trial. © 2007 The Royal College of Radiologists.
Persistent Identifierhttp://hdl.handle.net/10722/83520
ISSN
2014 Impact Factor: 3.398
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChoi, CKKen_HK
dc.contributor.authorChan, RTTen_HK
dc.contributor.authorTung, SYen_HK
dc.contributor.authorLui, Len_HK
dc.contributor.authorSiu, Sen_HK
dc.contributor.authorAu, GKHen_HK
dc.contributor.authorHo, JWCen_HK
dc.contributor.authorLaw, WLen_HK
dc.date.accessioned2010-09-06T08:42:01Z-
dc.date.available2010-09-06T08:42:01Z-
dc.date.issued2008en_HK
dc.identifier.citationClinical Oncology, 2008, v. 20 n. 2, p. 168-175en_HK
dc.identifier.issn0936-6555en_HK
dc.identifier.urihttp://hdl.handle.net/10722/83520-
dc.description.abstractAims: A phase II trial was initiated to evaluate the efficacy and toxicity of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic colorectal cancer. Patients and methods: Patients received a combination of CPT-11 plus capecitabine. CPT-11 was infused intravenously on day 1 every 2 weeks and oral capecitabine was taken twice daily for 5 days every 7 days. Efficacy and toxicities were assessed. Results: Between 2004 and 2005, 43 patients were enrolled. The overall response rate was 51.35%. With a median follow-up of 13 months, the median time to progression was 10 months (95% confidence interval 7.6-12.3 months); the median survival was 15 months (95% confidence interval 13.9-16.9 months). The most common grade 3 haematological and non-haematological toxicities were neutropenia (5.4%), diarrhoea (8.1%) and hand-foot syndrome (2.7%). Conclusions: CPT-11 plus capecitabine with a 14 day cycle showed a comparable response with international phase II data with a 3 weekly regimen and was well tolerated as a first-line palliative chemotherapy in patients with metastatic colorectal cancer. The data should be interpreted with caution due to the limited sample size and should be further confirmed by a phase III randomised trial. © 2007 The Royal College of Radiologists.en_HK
dc.languageengen_HK
dc.publisherWB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/clonen_HK
dc.relation.ispartofClinical Oncologyen_HK
dc.subjectCapecitabineen_HK
dc.subjectCPT-11en_HK
dc.subjectirinotecanen_HK
dc.subjectmetastatic colorectal canceren_HK
dc.titleEfficacy of Combination Chemotherapy with Irinotecan (CPT-11) plus Capecitabine in Patients with Metastatic or Advanced Colorectal Carcinoma - a Dual-centre Phase II Study: the MAC-6en_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0936-6555&volume=20&issue=2&spage=168&epage=175&date=2008&atitle=Efficacy+of+combination+chemotherapy+with+irinotecan+(CPT-11)+plus+capecitabine+in+patients+with+metastatic+or+advanced+colorectal+carcinoma+-+a+dual-centre+phase+II+study:+the+MAC-6en_HK
dc.identifier.emailLaw, WL: lawwl@hkucc.hku.hken_HK
dc.identifier.authorityLaw, WL=rp00436en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.clon.2007.11.008en_HK
dc.identifier.pmid18155454en_HK
dc.identifier.scopuseid_2-s2.0-39049165189en_HK
dc.identifier.hkuros141229en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-39049165189&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume20en_HK
dc.identifier.issue2en_HK
dc.identifier.spage168en_HK
dc.identifier.epage175en_HK
dc.identifier.isiWOS:000254160500009-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridChoi, CKK=22952868600en_HK
dc.identifier.scopusauthoridChan, RTT=8663654400en_HK
dc.identifier.scopusauthoridTung, SY=7102858954en_HK
dc.identifier.scopusauthoridLui, L=8232203800en_HK
dc.identifier.scopusauthoridSiu, S=12040146600en_HK
dc.identifier.scopusauthoridAu, GKH=7003748615en_HK
dc.identifier.scopusauthoridHo, JWC=7402649983en_HK
dc.identifier.scopusauthoridLaw, WL=7103147867en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats